Skip to main content
Bildspel: 

Emtrix launch in Southeast Asia initiated in Malaysia

Moberg Pharma’s partner in Southeast Asia and China, Menarini APAC, has initiated the launch in Malaysia of Moberg Pharma’s prescription-free treatment for nail fungus. The product is launched under Moberg’s brand Emtrix®

“During this week I had the pleasure of following the launch preparations on site in Southeast Asia when visiting the head office of Menarini APAC. It will be very exciting to follow the response in the market in Malaysia – our first market in the region. The growth potential for our brand in Southeast Asia and China is significant”, says Peter Wolpert, CEO of Moberg Pharma

About Moberg Pharma AB
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.com.